Alios BioPharma, Inc.
260 E Grand Ave Fl 2
South San Francisco, CA 94080-4811
Alios is a biotechnology company located in South San Francisco, California that is developing novel medicines that treat viral diseases. Alios has two platform technologies: small molecule activators of the RNase-L pathway and novel nucleoside/nucleotide chemistries. These complementary technologies have the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS). Alios has a staff of 28 full time employees, of which 22 are scientists, working in a 20,000 square foot facility. Alios management has discovered or led the development of numerous compounds that have reached the clinic for the treatment of chronic hepatitis C including: Infergen, Pegasys, RG7227, R1626, RG7128, and RG7348. We are funded by an experienced group of Venture Capital backers with extensive industry experience including: Novo A/S, Novartis Ventures, Roche Ventures, and SR-One (GlaxoSmithKline ventures).
Clinical Development Stage